medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-8-80-85medalphabet-2610Research ArticleДЕТСКАЯ ДЕРМАТОЛОГИЯPEDIATRIC DERMATOLOGYВажность и перспективы изучения выживаемости генно-инженерной биологической терапии при псориазе у детейImportance and prospects of studying survival of genetically engineered biological therapy for psoriasis in childrenhttps://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovR. A.

 Иванов Роман Александрович, врач-дерматовенеролог отделения дерматологии с группой лазерной хирургии НИИ детской дерматологии 

 Ivanov Roman A., dermatovenereologist of Dept of Dermatology with Laser Surgery Group of the Research Institute of Pediatric Dermatology

isxiks@gmail.comФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава РоссииРоссияNational Medical Research Centre for Children’s HealthRussian Federation20221805202208Дерматология (1)8085Copyright © Иванов Р.А., 20222022Иванов Р.А.Ivanov R.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2610

Пациенты детского возраста, страдающие псориазом, для поддержания долговременной ремиссии, как правило, нуждаются в длительной терапии генно-инженерными биологическими препаратами (ГИБП), которую они продолжают и после достижения совершеннолетнего возраста. Однако с течением времени наблюдается снижение эффективности биологической терапии вплоть до полной потери терапевтического ответа, в результате чего появляется необходимость смены ГИБП. В связи с этим актуальной темой для проведения исследований становится изучение показателя выживаемости биологической терапии и влияющих на него условий и факторов, что позволит реализовать персонифицированный подход в назначении ГИБП и улучшить эффективность проводимого лечения. В данной статье приведена информация об основных аспектах выживаемости биологической терапии у детей с псориазом, а также изложены результаты исследований по данной проблеме.

Pediatric patients with psoriasis, in order to maintain long-term remission, as a rule, need long-term therapy with genetically engineered biological drugs (GEBDs), which they continue after reaching adulthood. However, over time, there is a decrease in the effectiveness of biological therapy up to the complete loss of the therapeutic response, resulting in the need to change the biological therapy. In this regard, the study of the survival rate of biological therapy and the conditions and factors influencing it is becoming an urgent topic for research, which will make it possible to implement a personalized approach to prescribing GEBA and improve the effectiveness of the treatment. This article provides information on the main aspects of the survival of biological therapy in children with psoriasis, as well as the results of research on this issue.

генно-инженерные биологические препаратывыживаемостьбиологическая терапиякоморбидные состоянияпсориаздетиgenetically engineered biological agentssurvivalbiological therapycomorbid conditionspsoriasischildrenReferencesCramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M J., Ollendorf D.A., & Wong P.K. (2008). Medication Compliance and Persistence: Terminology and Defnitions. Value in Health, 11 (1), 44–47. DOI: 10.1111/j.1524–4733.2007.00213.x.Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M J., Ollendorf D.A., & Wong P.K. (2008). Medication Compliance and Persistence: Terminology and Defnitions. Value in Health, 11 (1), 44–47. DOI: 10.1111/j.1524–4733.2007.00213.x.No D.J., Inkeles M.S., Amin M., & Wu J.J. (2017). Drug survival of biologic treatments in psoriasis: a systematic review. Journal of Dermatological Treatment, 29 (5), 460–466. DOI: 10.1080/09546634.2017.1398393.No D.J., Inkeles M.S., Amin M., & Wu J.J. (2017). Drug survival of biologic treatments in psoriasis: a systematic review. Journal of Dermatological Treatment, 29 (5), 460–466. DOI: 10.1080/09546634.2017.1398393.Menter A., Gottlieb A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58 (5): 826–50. DOI: 10.1016/j.jaad.2008.02.039.Menter A., Gottlieb A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58 (5): 826–50. DOI: 10.1016/j.jaad.2008.02.039.Pinson R., Sotoodian B., Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016; 6: 121–129. Published 2016 Oct 20. DOI: 10.2147/PTT.S87650.Pinson R., Sotoodian B., Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016; 6: 121–129. Published 2016 Oct 20. DOI: 10.2147/PTT.S87650.Мурашкин Н.Н., Круглова Л.С. и соавт. Коморбидности псориаза в детском возрасте. Вопросы современной педиатрии. 2020; 19 (6): 460–467. DOI: 10.15690/vsp.v19i6.2149.Murashkin N.N., Kruglova L.S. et al. Comorbidity of psoriasis in childhood. Questions of modern pediatrics. 2020; 19 (6): 460–467. DOI: 10.15690/vsp.v19i6.2149.Augustin M., Glaeske G., et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010 Mar; 162 (3): 633–6. DOI: 10.1111/j.1365–2133.2009.09593.x.Augustin M., Glaeske G., et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010 Mar; 162 (3): 633–6. DOI: 10.1111/j.1365–2133.2009.09593.x.Н. Н. Мурашкин, Э. Т. Амбарчян, А. И. Материкин, Р. В. Епишев. Тяжелые формы псориаза в детском возрасте. Фарматека. 2016; 11 (324): 34–39.N.N. Murashkin, E.T. Ambarchyan, A.I. Materikin, R.V. Epishev. Severe forms of psoriasis in childhood. Pharmateka. 2016; 11 (324): 34–39.Gelfand J. M., Weinstein R., Porter S. B., Neimann A. L., Berlin J. A., Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005 Dec; 141 (12): 1537–41. DOI: 10.1001/archderm.141.12.1537.Gelfand J. M., Weinstein R., Porter S. B., Neimann A. L., Berlin J. A., Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005 Dec; 141 (12): 1537–41. DOI: 10.1001/archderm.141.12.1537.Kubanov A. A., Bogdanova E. V. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik Dermatologii i Venerologii. 2019; 95 (4): 8–23. https://doi.org/10.25208/0042–4609–2019–95–4–8–23.Kubanov A. A., Bogdanova E. V. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik Dermatologii i Venerologii. 2019; 95 (4): 8–23. https://doi.org/10.25208/0042–4609–2019–95–4–8–23.Elvina M. Pediatric Psoriasis: Clinical Features and Course. 2020. 1 (5) OAJBS. ID.000147.Elvina M. Pediatric Psoriasis: Clinical Features and Course. 2020. 1 (5) OAJBS. ID.000147.Greb J., Goldminz A., Elder J. et al. Psoriasis. Nat Rev Dis Primers 2, 16082 (2016). https://doi.org/10.1038/nrdp.2016.82.Greb J., Goldminz A., Elder J. et al. Psoriasis. Nat Rev Dis Primers 2, 16082 (2016). https://doi.org/10.1038/nrdp.2016.82.Raharja A., Mahil S.K., Barker J.N. Psoriasis: a brief overview. Clin Med (Lond). 2021 May; 21 (3): 170–173. DOI: 10.7861/clinmed.2021–0257.Raharja A., Mahil S.K., Barker J.N. Psoriasis: a brief overview. Clin Med (Lond). 2021 May; 21 (3): 170–173. DOI: 10.7861/clinmed.2021–0257.Mahil S. K., Capon F., Barker J. N. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016; 38 (1): 11–27. DOI: 10.1007/s00281–015–0539–8.Mahil S. K., Capon F., Barker J. N. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016; 38 (1): 11–27. DOI: 10.1007/s00281–015–0539–8.Мурашкин Н.Н., Круглова Л.С. и соавт. Коморбидности псориаза в детском возрасте. Вопросы современной педиатрии. 2020; 19 (6): 460–467. DOI: 10.15690/vsp.v19i6.2149.Murashkin N.N., Kruglova L.S. et al. Comorbidity of psoriasis in childhood. Questions of modern pediatrics. 2020; 19 (6): 460–467. DOI: 10.15690/vsp.v19i6.2149.Мурашкин Н. Н., Материкин А. И., Амбарчян Э. Т. и соавт. Псориаз и псориатический артрит в детском возрасте. Вопросы современной педиатрии. 2020; 19 (6): 444–451. DOI: 10.15690/vsp.v19i6.2146.Murashkin N. N., Materikin A. I., Ambarchyan E. T. et al. Psoriasis and psoriatic arthritis in childhood. Questions of modern pediatrics. 2020; 19 (6): 444–451. DOI: 10.15690/vsp.v19i6.2146.Н. Н. Мурашкин, А. А. Хотко, А. И. Материкин. Особенности течения псориаза у подростков: результаты проспективного наблюдения. Клиническая дерматология и венерология. 2013; 11 (6): 82–85.N.N. Murashkin, A.A. Khotko, A.I. Mainland. Features of the course of psoriasis in adolescents: results of a prospective observation. Clinical dermatology and venereology. 2013; 11 (6): 82–85.Намазова-Баранова Л. С., Мурашкин Н. Н., Амбарчян Э. Т., Материкин А.И. Системная терапия псориаза в детском возрасте (часть II): вопросы биологической терапии. Вестник дерматологии и венерологии. 2017; (6): 100–107. DOI: 10.25208/0042–4609–2017–93–6–100–107.Namazova-Baranova L. S., Murashkin N.N., Ambarchyan E.T., Materikin A.I. Systemic therapy of psoriasis in childhood (part II): issues of biological therapy. Bulletin of dermatology and venereology. 2017; (6): 100–107. DOI: 10.25208/0042–4609–2017–93–6–100–107.Л.С. Намазова-Баранова, Н.Н. Мурашкин, Э.Т. Амбарчян, А.И. Материкин. Системная терапия псориаза в детском возрасте (часть I). Вестник дерматологии и венерологии. 2017. № 4. С. 74–81.L. S. Namazova-Baranova, N. N. Murashkin, E. T. Ambarchyan, A. I. Mainland. Systemic therapy for psoriasis in childhood (part I). Bulletin of dermatology and venereology. 2017. No. 4. P. 74–81.Намазова-Баранова Л.С., Бакулев А. Л., Мурашкин Н. Н., Нам Л. Н., Иванов Р. А. Лечение среднетяжелого и тяжелого псориаза у детей: новые возможности генно-инженерной биологической терапии. Вопросы современной педиатрии. 2021; 20 (5): 446–450. DOI: 10.15690/vsp.v20i5.2322.Namazova-Baranova L.S., Bakulev A. L., Murashkin N. N., Nam L. N., Ivanov R. A. Treatment of moderate and severe psoriasis in children: new opportunities for genetically engineered biological therapy. Questions of modern pediatrics. 2021; 20 (5): 446–450. DOI: 10.15690/vsp.v20i5.2322.Leonardi C.L., Kimball A.B., et. Al. PHOENIX 1 study investigators. Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17; 371 (9625): 1665–74. DOI: 10.1016/S0140–6736 (08)60725–4.Leonardi C.L., Kimball A.B., et. Al. PHOENIX 1 study investigators. Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17; 371 (9625): 1665–74. DOI: 10.1016/S0140–6736 (08)60725–4.Papp K. A., Langley R. G., et. Al. Effcacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013 Feb; 168 (2): 412–21. DOI: 10.1111/bjd.12110.Papp K. A., Langley R. G., et. Al. Effcacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013 Feb; 168 (2): 412–21. DOI: 10.1111/bjd.12110.Мурашкин Н. Н., Амбарчян Э. Т., Епишев Р. В. и соавт. Эффективность и безопасность устекинумаба у детей с бляшечной, эритродермической и ладонно-подошвенной формами псориаза: ретроспективное когортное исследование. Вопросы современной педиатрии. 2020; 19 (6): 531–537. DOI: 10.15690/vsp.v19i6.2153.Murashkin N. N., Ambarchyan E. T., Epishev R. V. et al. Effcacy and safety of ustekinumab in children with plaque, erythrodermic, and palmoplantar psoriasis: a retrospective cohort study. Questions of modern pediatrics. 2020; 19 (6): 531–537. DOI: 10.15690/vsp.v19i6.2153.Landells I., Marano C., Hsu M.C. et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015; 73: 594–603.Landells I., Marano C., Hsu M.C. et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015; 73: 594–603.Griffths C.E., Strober B.E., van de Kerkhof P., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14; 362 (2): 118–28.Griffths C.E., Strober B.E., van de Kerkhof P., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14; 362 (2): 118–28.Мурашкин Н. Н., Амбарчян Э. Т. Сравнительная оценка эффективности и безопасности ингибиторов TNFα и IL12/23 в терапии псориаза у детей. Педиатрическая фармакология. 2018; 15 (6): 455–463. DOI: 10.15690/pf.v15i6.1983.Murashkin N.N., Ambarchyan E.T. Comparative evaluation of the effcacy and safety of TNFα and IL12/23 inhibitors in the treatment of psoriasis in children. Pediatric pharmacology. 2018; 15 (6): 455–463. DOI: 10.15690/pf.v15i6.1983.Kaushik S.B., Lebwohl M.G. Review of safety and effcacy of approved systemic psoriasis therapies. Int J Dermatol. 2019 Jun; 58 (6): 649–658. DOI: 10.1111/ijd.14246.Kaushik S.B., Lebwohl M.G. Review of safety and effcacy of approved systemic psoriasis therapies. Int J Dermatol. 2019 Jun; 58 (6): 649–658. DOI: 10.1111/ijd.14246.Mariette X., Tubach F., Bagheri H., et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010; 69 (2): 400–408. DOI: 10.1136/ard.2009.117762.Mariette X., Tubach F., Bagheri H., et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010; 69 (2): 400–408. DOI: 10.1136/ard.2009.117762.Mankia S., Peters J.E., Kang S., Moore S., Ehrenstein M.R. Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol. 2011 Mar; 30 (3): 399–401. DOI: 10.1007/s10067–010–1605–1.Mankia S., Peters J.E., Kang S., Moore S., Ehrenstein M.R. Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol. 2011 Mar; 30 (3): 399–401. DOI: 10.1007/s10067–010–1605–1.Lezcano Carduz V. P., Mingo Botín D., Durán Poveda S. P. Squamous Cell Neoplasm of the Ocular Surface in a Patient with Psoriasis Treated With Tumor Necrosis Factor-Alpha Inhibitors. Cornea. 2015 Jul; 34 (7): 833–4. DOI: 10.1097/ICO.0000000000000465.Lezcano Carduz V. P., Mingo Botín D., Durán Poveda S. P. Squamous Cell Neoplasm of the Ocular Surface in a Patient with Psoriasis Treated With Tumor Necrosis Factor-Alpha Inhibitors. Cornea. 2015 Jul; 34 (7): 833–4. DOI: 10.1097/ICO.0000000000000465.Diak P., Siegel J., et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010 Aug; 62 (8): 2517–24. DOI: 10.1002/art.27511.Diak P., Siegel J., et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010 Aug; 62 (8): 2517–24. DOI: 10.1002/art.27511.McCroskery P., Wallace C.A., et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J. 2010 Jun 14; 8: 18. DOI: 10.1186/1546–0096–8–18.McCroskery P., Wallace C.A., et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J. 2010 Jun 14; 8: 18. DOI: 10.1186/1546–0096–8–18.Paller A.S., Siegfried E.C., et al. Long-term safety and effcacy of etanercept in children and adolescents with plaque psoriasis. Journal of the American Academy of Dermatology, 2016; 74 (2), 280–287. e3. DOI: 10.1016/j.jaad.2015.09.056.Paller A.S., Siegfried E.C., et al. Long-term safety and effcacy of etanercept in children and adolescents with plaque psoriasis. Journal of the American Academy of Dermatology, 2016; 74 (2), 280–287. e3. DOI: 10.1016/j.jaad.2015.09.056.Papp K., Thaçi D., et. al Effcacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. The Lancet, 2017. 390 (10089), 40–49. DOI: 10.1016/s0140–6736 (17)31189–3.Papp K., Thaçi D., et. al Effcacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. The Lancet, 2017. 390 (10089), 40–49. DOI: 10.1016/s0140–6736 (17)31189–3.Zangrilli A., Bavetta M., & Bianchi L. (2020). Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opinion on Drug Safety. DOI: 10.1080/14740338.2020.1752659.Zangrilli A., Bavetta M., & Bianchi L. (2020). Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opinion on Drug Safety. DOI: 10.1080/14740338.2020.1752659.Thaçi D., Papp K. et. al Sustained Long-Term Effcacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double-Blind, Phase 3 Study. British Journal of Dermatology. 2019. DOI: 10.1111/bjd.18029.Thaçi D., Papp K. et. al Sustained Long-Term Effcacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double-Blind, Phase 3 Study. British Journal of Dermatology. 2019. DOI: 10.1111/bjd.18029.Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018; 9 (8): 147–158. DOI: 10.1177/2040622318772705.Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018; 9 (8): 147–158. DOI: 10.1177/2040622318772705.Kalb R.E, Fiorentino D.F. et. al Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015 Sep; 151 (9): 961–9. DOI: 10.1001/jamadermatol.2015.0718.Kalb R.E, Fiorentino D.F. et. al Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015 Sep; 151 (9): 961–9. DOI: 10.1001/jamadermatol.2015.0718.Kellen Roselyn et al. Effcacy and safety of ustekinumab in adolescents. Pediatric health, medicine and therapeutics. Vol. 7. 19 Sep. 2016. 109–120. DOI: 10.2147/PHMT.S75836.Kellen Roselyn et al. Effcacy and safety of ustekinumab in adolescents. Pediatric health, medicine and therapeutics. Vol. 7. 19 Sep. 2016. 109–120. DOI: 10.2147/PHMT.S75836.Magnolo N., et al. A phase III open-label, randomized multicenter study to evaluate effcacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2021: S0190–9622 (21) 02509–3. DOI: 10.1016/j.jaad.2021.08.066.Magnolo N., et al. A phase III open-label, randomized multicenter study to evaluate effcacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2021: S0190–9622 (21) 02509–3. DOI: 10.1016/j.jaad.2021.08.066.Van den Reek, J.M.P.A., Kievit W., et al. Drug Survival Studies in Dermatology: Principles, Purposes, and Pitfalls. Journal of Investigative Dermatology, 2015; 135 (7), 1–5. DOI: 10.1038/jid.2015.171.Van den Reek, J.M.P.A., Kievit W., et al. Drug Survival Studies in Dermatology: Principles, Purposes, and Pitfalls. Journal of Investigative Dermatology, 2015; 135 (7), 1–5. DOI: 10.1038/jid.2015.171.Di Meglio, Paola et al. Psoriasis. Cold Spring Harbor perspectives in medicine. Vol. 4, 8 a015354. 1 Aug. 2014, DOI: 10.1101/cshperspect.a015354.Di Meglio, Paola et al. Psoriasis. Cold Spring Harbor perspectives in medicine. Vol. 4, 8 a015354. 1 Aug. 2014, DOI: 10.1101/cshperspect.a015354.Phan C., Beauchet A., et al. Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019. DOI: 10.1111/jdv.15579.Phan C., Beauchet A., et al. Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019. DOI: 10.1111/jdv.15579.Gniadecki R., Bang B., et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. British Journal of Dermatology, 2014; 172 (1), 244–252. DOI: 10.1111/bjd.13343.Gniadecki R., Bang B., et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. British Journal of Dermatology, 2014; 172 (1), 244–252. DOI: 10.1111/bjd.13343.Strober B.E., Bissonnette R., et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016 May; 74 (5): 851–61. e4. DOI: 10.1016/j.jaad.2015.12.017.Strober B.E., Bissonnette R., et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016 May; 74 (5): 851–61. e4. DOI: 10.1016/j.jaad.2015.12.017.Warren R.B., Smith, et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015; 135 (11), 2632–2640. DOI: 10.1038/jid.2015.208.Warren R.B., Smith, et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015; 135 (11), 2632–2640. DOI: 10.1038/jid.2015.208.Fleming P., Kraft J., Gulliver W.P., Lynde C. The Relationship of Obesity with the Severity of Psoriasis: A Systematic Review. J Cutan Med Surg. 2015 Sep-Oct; 19 (5): 450–6. DOI: 10.1177/1203475415586332.Fleming P., Kraft J., Gulliver W.P., Lynde C. The Relationship of Obesity with the Severity of Psoriasis: A Systematic Review. J Cutan Med Surg. 2015 Sep-Oct; 19 (5): 450–6. DOI: 10.1177/1203475415586332.Paller A.S., Mercy K., Kwasny M.J., Choon S.E., Cordoro K.M., Girolomoni G., Menter A., Tom W.L., Mahoney A.M., Oostveen A.M., Seyger M.M. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013 Feb; 149 (2): 166–76. DOI: 10.1001/jamadermatol.2013.1078.Paller A.S., Mercy K., Kwasny M.J., Choon S.E., Cordoro K.M., Girolomoni G., Menter A., Tom W.L., Mahoney A.M., Oostveen A.M., Seyger M.M. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013 Feb; 149 (2): 166–76. DOI: 10.1001/jamadermatol.2013.1078.Cerveró A.D., Cardona G., Morales A., et al. 4CPS-041 Drug survival of biologic therapies for the treatment of psoriasisEuropean Journal of Hospital Pharmacy 2018; 25: A59–A60.Cerveró A.D., Cardona G., Morales A., et al. 4CPS-041 Drug survival of biologic therapies for the treatment of psoriasisEuropean Journal of Hospital Pharmacy 2018; 25: A59–A60.Jacobi A., Rustenbach S.J., & Augustin M. (2015). Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. International Journal of Dermatology, 55 (3), 296–302. DOI: 10.1111/ijd.12879.Jacobi A., Rustenbach S.J., & Augustin M. (2015). Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. International Journal of Dermatology, 55 (3), 296–302. DOI: 10.1111/ijd.12879.Yiu Z.Z.N., Mason K.J., Hampton P.J., et al. BADBIR Study Group. Drug survival of adalimumab, ustekinumab, and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) [published online March 2, 2020. Br J Dermatol. DOI: 10.1111/bjd.18981.Yiu Z.Z.N., Mason K.J., Hampton P.J., et al. BADBIR Study Group. Drug survival of adalimumab, ustekinumab, and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) [published online March 2, 2020. Br J Dermatol. DOI: 10.1111/bjd.18981.Antoniou C., Dessinioti C., Stratigos A., et al. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profle and predictors of response based on a single institution’s experience. J Eur Acad Dermatol Venereol. 2009; 23: 979–982.Antoniou C., Dessinioti C., Stratigos A., et al. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profle and predictors of response based on a single institution’s experience. J Eur Acad Dermatol Venereol. 2009; 23: 979–982.Papp K.A., Langley R.G., Lebwohl M., et al. Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2). Lancet. 2008; 371: 1675–1684.Papp K.A., Langley R.G., Lebwohl M., et al. Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2). Lancet. 2008; 371: 1675–1684.Kishimoto M., Komine M., et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. The Journal of Dermatology, 2019. DOI: 10.1111/1346–8138.15146.Kishimoto M., Komine M., et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. The Journal of Dermatology, 2019. DOI: 10.1111/1346–8138.15146.Van den Reek J. M.P.A., Tummers M., et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. Journal of the European Academy of Dermatology and Venereology, 2014; 29 (3), 560–565. DOI: 10.1111/jdv.12636.Van den Reek J. M.P.A., Tummers M., et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. Journal of the European Academy of Dermatology and Venereology, 2014; 29 (3), 560–565. DOI: 10.1111/jdv.12636.Vermeire S., Noman M., van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007 Sep; 56 (9): 1226–31.Vermeire S., Noman M., van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007 Sep; 56 (9): 1226–31.Gottlieb A. B., Langley R. G., Strober B. E., et al. A randomized, double-blind, placebocontrolled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012 Sep; 167 (3): 649–57.Gottlieb A. B., Langley R. G., Strober B. E., et al. A randomized, double-blind, placebocontrolled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012 Sep; 167 (3): 649–57.Shalom G., Cohen A.D., et al. Biologic drug survival in Israeli psoriasis patients. Journal of the American Academy of Dermatology, 2017; 76 (4), 662–669. e1. DOI: 10.1016/j.jaad.2016.10.033.Shalom G., Cohen A.D., et al. Biologic drug survival in Israeli psoriasis patients. Journal of the American Academy of Dermatology, 2017; 76 (4), 662–669. e1. DOI: 10.1016/j.jaad.2016.10.033.Zorlu O., Bülbül Başkan E., et al. Predictors of drug survival of biologic therapies in psoriasis patients. Journal of Dermatological Treatment. 2020; 1–17. DOI: 10.1080/09546634.2020.1763240.Zorlu O., Bülbül Başkan E., et al. Predictors of drug survival of biologic therapies in psoriasis patients. Journal of Dermatological Treatment. 2020; 1–17. DOI: 10.1080/09546634.2020.1763240.Иванов Р.А., Мурашкин Н.Н. Выживаемость биологической терапии у детей, страдающих псориазом: когортное исследование. Вопросы современной педиатрии. 2021; 20 (5): 451–458. DOI: 10.15690/vsp.v20i5.2323.Ivanov R. A., Murashkin N. N. Survival of biological therapy in children with psoriasis: a cohort study. Questions of modern pediatrics. 2021; 20(5): 451–458. DOI: 10.15690/vsp.v20i5.2323

The authors declare that there are no conflicts of interest present.